A groundbreaking human trial of ER-100, a cellular reprogramming therapy, has begun, testing whether damaged eye cells can be rejuvenated and potentially opening a new chapter in the science of aging.

A team linked to Harvard Medical School has dosed the first patient in a clinical trial designed to reverse cellular aging in ...

Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...

Blindness itself might become, at least in certain cases, partially reversible. This potential future stems from one of the ...

More years of mobility and independence, and fewer prolonged periods of illness later in life, is certainly alluring, but is ...

A Boston biotech company has administered what researchers are describing as the first human dose of a cellular rejuvenation drug, a milestone in the effort to treat age-related disease at the ...

Could this work to prevent blindness and eventually turn back the clock in other organs too?

As Dubai continues to strengthen its position as a global hub for longevity, health innovation and advanced medicine, Next ...

Lkb1-mutant lung tumors release prostaglandin E2, triggering signaling via lung sensory neurons and the vagus nerve to reduce ...

What sets Kurzweil apart from many futurists is his track record. Over several decades, he correctly anticipated the rise of the internet as a dominant global communications platform, the emergence of ...

A new book by New York Times reporters Maggie Haberman and Jonathan Swan claims JD Vance suggested India and Saudi Arabia as possible peacekeepers in Ukraine during an Oval Office meeting. According ...

A cutting-edge mini-review published in the inaugural issue of Targetome elaborates on the value of proteome-wide ...